{
    "clinical_study": {
        "@rank": "73",
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on April 14, 2020",
            "link_text": "Link to the current ClinicalTrials.gov record.",
            "url": "https://clinicaltrials.gov/show/NCT04337216"
        },
        "id_info": {
            "org_study_id": "HM20019145",
            "nct_id": "NCT04337216"
        },
        "brief_title": "Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation",
        "official_title": "Mavrilimumab to Reduce Progression of Acute Respiratory Failure in Patients With Severe COVID-19 Pneumonia and Systemic Hyper-inflammation",
        "sponsors": {
            "lead_sponsor": {
                "agency": "Virginia Commonwealth University",
                "agency_class": "Other"
            }
        },
        "source": "Virginia Commonwealth University",
        "oversight_info": {
            "is_fda_regulated_drug": "Yes",
            "is_fda_regulated_device": "No",
            "is_us_export": "No"
        },
        "brief_summary": {
            "textblock": "The primary endpoint of this study is to assess the effects of a single IV dose of\n      mavrilimumab on the acute inflammatory response in patients with severe COVID-19 pneumonia"
        },
        "overall_status": "Not yet recruiting",
        "start_date": {
            "@type": "Anticipated",
            "#text": "April 2020"
        },
        "completion_date": {
            "@type": "Anticipated",
            "#text": "July 2020"
        },
        "primary_completion_date": {
            "@type": "Anticipated",
            "#text": "July 2020"
        },
        "phase": "Phase 2",
        "study_type": "Interventional",
        "has_expanded_access": "No",
        "study_design_info": {
            "intervention_model": "Single Group Assignment",
            "primary_purpose": "Treatment",
            "masking": "None (Open Label)"
        },
        "primary_outcome": {
            "measure": "Time to resolution of fever",
            "time_frame": "Up to 28 days",
            "description": "Body temperature will be measured in celsius"
        },
        "secondary_outcome": [
            {
                "measure": "Change in clinical status",
                "time_frame": "Baseline to up to 28 days",
                "description": "Clinical status will be assessed using 6-category scale: 1. Not hospitalized, 2. Hospitalized, no supplemental oxygen, 3. Hospitalized, on supplemental oxygen, 4. Hospitalized, requiring nasal high-flow oxygen or non-invasive ventilation, 5. Hospitalized, requiring ECMO, invasive mechanical ventilation or both, 6. Death."
            },
            {
                "measure": "Mortality",
                "time_frame": "28 days",
                "description": "Number of deaths during 28 day follow-up period"
            },
            {
                "measure": "Change in CRP",
                "time_frame": "Baseline to up to 28 days or discharge",
                "description": "Change in CRP levels"
            },
            {
                "measure": "Change in IL-6",
                "time_frame": "Baseline to up to 28 days or discharge",
                "description": "Change in IL-6 levels"
            }
        ],
        "number_of_arms": "1",
        "enrollment": {
            "@type": "Anticipated",
            "#text": "10"
        },
        "condition": "COVID-19",
        "arm_group": {
            "arm_group_label": "Mavrilimumab",
            "arm_group_type": "Experimental"
        },
        "intervention": {
            "intervention_type": "Drug",
            "intervention_name": "Mavrilimumab",
            "description": "single IV dose of mavrilimumab",
            "arm_group_label": "Mavrilimumab"
        },
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented COVID19 pneumonia (positive SARS-CoV2 test, bilateral abnormalities/\n             infiltrates on chest x-ray or computed tomography, active fever or documented fever\n             within 24-48 or ongoing anti-pyretic use to suppress fever).\n\n          -  Hypoxia (room air SpO2 <92% or requirement for supplemental oxygen).\n\n          -  Increased serum inflammatory markers (CRP > 5 mg/dl AND LDH >upper limit of normal for\n             local laboratory).\n\n        Exclusion Criteria:\n\n          -  Onset of COVID-19 >14 days\n\n          -  Hospitalized >7 days\n\n          -  Mechanically ventilated\n\n          -  Age <18 years-old\n\n          -  Neutropenia (absolute neutrophil count <1,500/mm3)\n\n          -  Serious concomitant illness which in the opinion of the investigator precludes the\n             patient from enrolling in the trial, including (but not limited to):\n\n               -  History of immunodeficiency (congenital or acquired)\n\n               -  History of solid-organ or bone marrow transplant\n\n               -  History of current systemic autoimmune or autoinflammatory disease(s) requiring\n                  systemic immune-modulating drugs\n\n               -  History of myeloproliferative disorder or active malignancy receiving cytotoxic\n                  chemotherapy\n\n               -  Pre-existing severe pulmonary disease (i.e. asthma, COPD, or others)\n\n               -  Pre-existing severe left ventricular systolic dysfunction (i.e. LVEF <35%)\n\n               -  Known active tuberculosis (TB) or history of incompletely treated TB or at high\n                  risk for latent TB (for exposure or prior incarceration)\n\n               -  Concomitant systemic bacterial or fungal infection\n\n               -  Concomitant viral infection other than COVD-19 (e.g. influenza)\n\n               -  History of chronic liver disease with portal hypertension\n\n               -  History of end-stage renal disease on chronic renal replacement therapy\n\n          -  Recent treatment with cell-depleting biological therapies (e.g., anti-CD20) within 12\n             months noncell-depleting biological therapies (such as anti-tumor necrosis\n             factor-alpha [TNF-alpha], anakinra, anti-Interleukin [IL]-6 receptor [e.g.\n             tocilizumab], or abatacept) within 8 weeks (or 5 half-lives, whichever is longer),\n             treatment with alkylating agents within 12 weeks, treatment with cyclosporine A,\n             azathioprine, cyclophosphamide, or mycophenolate mofetil (MMF) within 4 weeks\n\n          -  Recent treatment with intramuscular live (attenuated) vaccine within the 4 weeks\n\n          -  Chronic or recent corticosteroid use\n\n          -  Pregnancy or lactation or newborn\n\n          -  Enrolled in another investigational study using immunosuppressive therapy\n\n          -  Enrolled in a blinded clinical trial of any type\n\n          -  Known hypersensitivity to Mavrilimumab or any of its excipients\n\n          -  In the opinion of the investigator, unable to comply with the requirements to\n             participate in the study"
            },
            "gender": "All",
            "minimum_age": "18 Years",
            "maximum_age": "N/A",
            "healthy_volunteers": "No"
        },
        "overall_official": {
            "last_name": "Antonio Abbate, MD, PhD",
            "role": "Principal Investigator",
            "affiliation": "Virginia Commonwealth University"
        },
        "location": {
            "facility": {
                "name": "Virginia Commonwealth University",
                "address": {
                    "city": "Richmond",
                    "state": "Virginia",
                    "zip": "23298",
                    "country": "United States"
                }
            }
        },
        "location_countries": {
            "country": "United States"
        },
        "verification_date": "April 2020",
        "study_first_submitted": "April 1, 2020",
        "study_first_submitted_qc": "April 3, 2020",
        "study_first_posted": {
            "@type": "Actual",
            "#text": "April 7, 2020"
        },
        "last_update_submitted": "April 3, 2020",
        "last_update_submitted_qc": "April 3, 2020",
        "last_update_posted": {
            "@type": "Actual",
            "#text": "April 7, 2020"
        },
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        },
        "condition_browse": {
            "mesh_term": [
                "Pneumonia",
                "Respiratory Insufficiency",
                "Inflammation"
            ]
        },
        "intervention_browse": {
            "mesh_term": [
                "Mavrilimumab",
                "Antibodies, Monoclonal"
            ]
        },
        "patient_data": {
            "sharing_ipd": "No"
        }
    }
}